13F Holdings
中文EN

TMCI TREACE MEDICAL CONCEPTS, INC.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1630627 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-7.1%
TTM net income YoY-11.3%
TTM EPS YoY-6.2%
Revenue 3-yr CAGR5.2%
Net income 3-yr CAGR—

Margins

Gross margin79.6%
Operating margin-24.4%
Net margin-27.4%
FCF margin-9.1%
EBITDA margin-21.1%

Returns

ROE-74.0%
ROA-29.7%
ROIC (approx.)-31.2%
Asset turnover1.08x

Leverage & solvency

Liabilities / assets65.6%
Debt / equity0.97x
Current ratio2.58x
Interest coverage-8.17x

Cash quality & payout

Operating cash flow / net income0.16x
Accruals ratio-25.0%
Payout ratio—
Capex / revenue4.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$212.69M$209.36M$187.12M$141.84M$94.42M
Cost of revenue$42.94M$41.09M$35.18M$25.53M$16.89M
Gross profit$169.75M$168.26M$151.94M$116.31M$77.53M
R&D expense$20.28M$20.59M$15.44M$13.58M$10.20M
SG&A expense$62.74M$55.72M$47.03M$33.00M$18.43M
Operating income-$54.15M-$55.69M-$51.43M-$34.84M-$16.51M
Interest expense$5.32M$5.26M$5.17M$4.40M$4.06M
Income tax$0$0$0$0$0
Net income-$59.00M-$55.74M-$49.53M-$42.81M-$20.55M
EBITDA-$43.53M-$47.27M-$46.08M-$32.71M-$15.82M
EPS (basic)-0.93-0.90-0.81-0.77-0.43
EPS (diluted)-0.93-0.90-0.81-0.77-0.43
Weighted avg. shares (diluted)63.27M62.11M60.85M55.28M48.42M
Balance sheet
Cash & equivalents$10.71M$11.35M$12.98M$19.47M$105.83M
Short-term investments$37.66M$64.33M$110.22M$61.78M$0
Receivables$42.16M$40.80M$38.10M$29.20M$18.57M
Inventory$36.03M$39.26M$29.25M$19.33M$10.56M
Current assets$132.05M$161.40M$198.36M$133.40M$137.97M
PP&E, net$29.75M$25.95M$22.30M$15.34M$2.85M
Goodwill$12.81M$12.81M$12.81M$0—
Intangibles$7.12M$8.07M$9.03M$0—
Total assets$190.58M$217.09M$251.91M$159.02M$140.82M
Current liabilities$30.64M$34.92M$45.03M$30.25M$18.21M
Short-term debt$1.75M$0———
Long-term debt$55.58M$53.31M$53.01M$52.71M$29.36M
Total debt$57.33M$53.31M$53.01M$52.71M$29.36M
Total liabilities$103.25M$104.20M$113.97M$98.50M$47.75M
Shareholders' equity$87.33M$112.89M$137.94M$60.53M$93.07M
Net debt$46.62M$41.96M$40.03M$33.24M-$76.47M
Shares outstanding——61.75M55.63M54.18M
Cash flow statement
Operating cash flow-$15.97M-$37.17M-$34.58M-$30.65M-$17.19M
Capital expenditure$13.52M$11.59M$11.46M$14.84M$2.71M
Free cash flow-$29.49M-$48.76M-$46.03M-$45.49M-$19.90M
Investing cash flow$13.25M$35.38M-$81.30M-$76.52M-$2.71M
Financing cash flow$2.08M$160,000$109.38M$20.81M$107.65M
Depreciation & amortization$10.62M$8.42M$5.35M$2.13M$685,000
Stock-based compensation$33.82M$30.60M$17.35M$8.11M$3.41M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.